Department of Pharmacology and Pharmacy, The University of Hong Kong

Professor Ian C.K. WONG 黃志基

Professor Ian C.K. WONG

Head of Department

Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy

Biography

Professor Wong is Co-Director of the Centre for Safe Medication Practice and Research, Department of Pharmacology & Pharmacy, and holder of the Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy at HKU. He is Co-Director of the Centre for Medication Optimisation Research and Education (CMORE) at University College London Hospital and UCL School of Pharmacy.

His expertise is using big data research to investigate safety and optimum use of medications for treatment of various conditions specifically cardiovascular, neurological and psychological conditions. As part of this work, he conducts research at Queen Mary Hospital, Hong Kong to evaluate the safety and effectiveness of medication in patients with these and other illnesses.

Professor Ian Wong and his research associates with Professor William Chui and Dr Esther Chan

Professor Ian Wong and his research associates with Professor William Chui and Dr Esther Chan


Professor Wong qualified as a pharmacist in 1992 and received his PhD from The University of Manchester in 1998 for his work at the David Lewis Centre for Epilepsy. In 2002, he was appointed as the Founding Director of the Centre for Paediatric Pharmacy Research at the School of Pharmacy, University of London, and the UCL Institute of Child Health and Great Ormond Street Hospital, which is recognised as a leading research centre in medicines for children.

After joining HKU in 2011 as Head of the Department of Pharmacology & Pharmacy, Professor Wong led the accreditation of the BPharm programme by the Pharmacy and Poisons Board of Hong Kong. He was also responsible for setting up the new Master of Clinical Pharmacy programme and the Centre for Safe Medication Practice and Research. The Centre for Safe Medication Practice and Research has focused on the methodological development and application of health big data research in Hong Kong. In 2015, in addition to his work at HKU, Professor Wong took up his dual role at UCL to develop a joint research programme in pharmacoepidemiology and medication safety.

Professor Wong has also advised the Departments of Health in England and Hong Kong, the World Health Organization, the European Medicines Agency, and the pharmaceutical industry. He has over 300 peer-reviewed papers published in prominent journals and is an Executive Editor of British Journal of Clinical Pharmacology. Professor Wong was cited among the top 1% of scholars in the Clarivate Analytics' Essential Science Indicators in five consecutive years between 2015 and 2019.

In recognition of his research, Professor Wong has received various awards and fellowships for his work as an academic pharmacist. He was awarded the Chemist and Druggist Pharmacy Practice Research Conference Medal from the Royal Pharmaceutical Society of Great Britain in 2004. He is the only pharmacist to date to have received a UK Department of Health Public Health Career Scientist Award in 2002. He was awarded an Honorary Fellowship from the Royal College of Paediatrics and Child Health in the UK in 2011, an Honorary Fellowship from the College of Pharmacy Practice in Hong Kong in 2013, and a Fellowship from the Royal Pharmaceutical Society of Great Britain in 2013, British Pharmacological Society 2019 and International Society of Pharmacovigilance in 2019.

Professor Wong was Vice-President of the International Society of Pharmacovigilance between 2016 and 2019. He has also been an expert witness for many legal cases in the UK and Hong Kong regarding medication safety on behalf of victims of medication errors and adverse drug reactions, and for pharmaceutical companies.

Memberships & Editorships

Memberships:

  • Honorary Fellow of Royal College of Paediatrics and Child Health (UK)
  • Fellow of British Pharmacological Society (UK)
  • Fellow of Royal Pharmaceutical Society (UK)
  • Fellow of College of Pharmacy Practice (HK)
  • Fellow of the Higher Education Academy (England)
  • Fellow of the Academy of Life Sciences for Chinese (UK)
  • Registered Pharmacist (UK & HK)
 

Editorships:

  • Executive Editor of British Journal of Clinical Pharmacology
  • Member of International Editorial Board of Drug Safety
  • Member of International Editorial Board of Pediatric Drugs
  • Member of International Editorial Board of CNS Drugs
Honours & Awards
  • Chemist and Druggist Pharmacy Practice Research Conference Medal by Royal Pharmaceutical Society of Great Britain 2004.
  • National Public Health Career Scientist Award by the Department of Health in England 2002.
  • John M Harrison Award (Travel) by the UK College of Pharmacy Practice 1999.

Research Interests
Medicines for Children
  • Development of appropriate medicines for children
  • Pharmaceutical care for children
  • Medication errors
Pharmacoepidemiology and Drug Safety
  • Pharmacovigilance
  • Methodological research
  • Drug utilization
Neuropsychopharmacology
  • Antiepileptic drugs
  • ADHD treatment
  • Antipsychotic drugs
  • Antidepressants

Publications
Publications Highlights

Lau WCY, Cheung CL, Man K, Chan E, Sing CW, Lip G, Siu DCW, Lam J, Lee ACH, Wong ICK*.

Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and the risk of osteoporotic fractures among patients with atrial fibrillation: A population-based cohort study. Annals of Internal Medicine. (In press April 2020).

Impact Factor (2018/2019): 19.32

 

Wong ICK, Banaschewski T, Buitelaar J, Cortese S, Döpfner M, Simonoff E, Coghill D; European ADHD Guidelines Group.

Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatry. 2019 Jun;6(6):528-537. doi: 10.1016/S2215-0366(19)30096-3.

Impact Factor (2018/2019): 19.32

 

Click to view:
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30096-3/fulltext

 

Brauer R, Lau WCY, Hayes JF, Man KKC, Osborn DPJ, Howard R, Kim J, Wong ICK*.

Trazodone use and risk of dementia: A population-based cohort study. PLoS Med. 2019 Feb 5;16(2):e1002728. doi: 10.1371/journal.pmed.1002728. eCollection 2019 Feb.

Impact Factor (2018/2019): 11.05

 

Click to view:
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002728 (Free download)

 

Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK*.

Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018 Oct;5(10):824-835. doi: 10.1016/S2215-0366(18)30293-1.

Impact Factor (2017/2018): 15.23

 

Click to view:
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30293-1/fulltext

Editorials: Why are stimulant medication prescriptions rising globally?
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30317-1/fulltext

 

Lau WC, Chan EW, Cheung CL, Sing CW, Man KK, Lip GY, Siu CW, Lam JK, Lee AC, Wong ICK*.

Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. JAMA. 2017 Mar 21;317(11):1151-1158. doi: https://doi.org/10.1001/jama.2017.1363

Impact Factor(2017/2018): 47.66

 

Click to view:
https://jamanetwork.com/journals/jama/article-abstract/2612616 (Free download)

 

Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK*.

Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017 May 31;357:j2350. doi: 10.1136/bmj.j2350.

Impact Factor (2017/2018): 23.56

 

Click to view:
http://www.bmj.com/content/357/bmj.j2350(open access)

Editorials. The safety of antidepressants in pregnancy BMJ 2017; 357
doi: https://doi.org/10.1136/bmj.j2544

 

Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, Häge A, Rosenthal E, Wong ICK*.

Association of Risk of Suicide Attempts With Methylphenidate Treatment. JAMA Psychiatry. 2017 Jul 26. doi: 10.1001/jamapsychiatry.2017.2183. [Epub ahead of print]

Impact Factor (2017/2018): 16.64

 

Click to view:
http://jamanetwork.com/journals/jamapsychiatry/article-abstract/2645499 (Free download)

 * Corresponding author

 

Contribution to The National Institute for Health and Care Excellence (NICE) reports:

 

Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. The National Institute for Health and Care Excellence Published date: 14 March 2018 (https://www.nice.org.uk/guidance/NG87)

 

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release/ The National Institute for Health and Care Excellence (NICE)advice [ESNM70] Published date: March 2016 (https://www.nice.org.uk/advice/esnm70/chapter/key-points-from-the-evidence)

 

Guidance on The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. The National Institute for Health and Care Excellence (NICE) 2012. (https://www.nice.org.uk/guidance/cg137)

 

Guidance on Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. The National Institute for Health and Care Excellence (NICE). 2009. (http://publications.nice.org.uk/attention-deficit-hyperactivity-disorder-cg72)

Selected Publications

 

  • Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA.
    Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019 Jan;19(1):67-75.
    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30547-4/fulltext
    Impact factor (2017/2018): 25.14

 

  • Hayes JF, Lundin A, Wicks S, Lewis G, Wong ICK, Osborn DPJ, Dalman C.
    Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness. JAMA Psychiatry. 2019 Jan 9. doi: 10.1001/jamapsychiatry.2018.3907.
    https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2719703 (Free download)
    Impact factor (2017/2018): 16.64

 

 

  • Leung WK, Wong IO, Cheung KS, Yeung KF, Chan EW, Wong AY, Chen L, Wong IC, Graham DY.
    Effects of Helicobacter PYLORI Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018 Mar 14. pii: S0016-5085(18)30322-6.
    https://www.gastrojournal.org/article/S0016-5085(18)30322-6/fulltext (Free download)
    Impact factor (2017/2018): 20.87

 

  • Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK.
    Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018 Jan;67(1):28-35.
    http://gut.bmj.com/content/67/1/28 (Free download)
    Impact factor (2017/2018):17.01

 

  • Guo CG, Cheung KS, Zhang F, Chan EW, Chen L, Wong IC, Leung WK.
    Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study. Gut. 2019 May 17. pii: gutjnl-2019-318352.
    https://gut.bmj.com/content/69/3/445
    Impact factor (2017/2018):17.01

 

* Corresponding author


Funding
Grant from Hong Kong Research Grant Council 
Agreement Code Years Funders and topic Value to HKU
As Principal Investigator
RGC Ref: C7009-19G 2020-2021 Research Grant Council Collaborative Research Fund (CRF):International Big Data Network for Attention Deficit and / Hyperactivity Disorder: Development and Application of Data Platform 2,203,537
17125419 2019-2020 Research Grant Council General Research Fund (GRF): Treatment for Attention Deficit Hyperactivity Disorder and Poisoning : Pharmaco-epidemiological Research (TAPPER) 339,770
As Co-investigator                                         355,839
17620919 2019-2020 Long-term impact of child maltreatment: A population-based longitudinal study                                         809,816
17106719 2019-2020 Predicting and Managing Cardiovascular Risk Factors in People with Schizophrenia: A Population-Based Cohort Study
Educational and research grants from industry and overseas:
Agreement Code Years Funders and topic Value to HKU
RS180303  2019-2020 Amgen Sponsor Research  Grant: The use, safety, and effectiveness of Prolia in clinical practice among women with post-menopausal osteoporosis in Hong Kong. 706,091
 
RS180293  2019-2020 GSK unconditional educational Grant: Pharmacoepidemiological study of the current Hong Kong HIV cohort: An evaluation of comorbidities and treatment regimens 300,000
 
RS180291  2019-2020 Novartis unconditional Educational Grant: Mortality and hospital readmission in patients with heart failure treated with angiotensin-neprilysin inhibitor versus enalapril 650,000
 
RS180379  2019-2020 Tung Wah Hospital Group Research Grant: Research Grant: The impact of automatic tablet dispensing and packaging system (ATDPS) in a rehabilitation complex 500,000
 
NHMRC no:GA30209 2019-2020 Austrialian National Health and Medical Research Council Research Grant. Large Scale evidence generation for the utilisation and safety of biologic medicines (adminster via University of University of South Austrialia) 330,000

Patents

 

Professor Wong is the Founder and a Director of Therakind Ltd
http://www.therakind.com/UK
Since Nov 2006

  • In association with UCL School of Pharmacy, UCL Institute Child Health and Great Ormond Street Children’s Hospital and IPSO Ventures Professor Wong set up Therakind Ltd.
  • Therakind is a commercial research organisation which works exclusively in paediatric drug research.
  • The first product (Buccolam®) was granted the first “Paediatric Use Marketing Authorisation” under the new European regulation at the beginning of 2012.
  • The second product (Ayendi®) was granted a product license by the Medicines and Healthcare products Agency in 2014.

Other Information
Research Collaborators

 

Seeking PhD candidates

We are seeking highly organised and motivated PhD candidates for research in the areas of medication safety, pharmacoepidemiology and pharmaceutical care in children and the elderly. Candidates with a background in healthcare may have an advantage, however it is not a requirement. For further information, please email Prof Ian Wong with your CV (email:wongick@hku.hk).

Selected media releases and communications

Treatment of psychiatric illness:

(Oriental Daily Chinese) 
http://orientaldaily.on.cc/cnt/news/20130201/00176_059.html

(Apple Daily Chinese) 
http://hk.apple.nextmedia.com/news/art/20130201/18153118

(BBC Website English) 
http://news.bbc.co.uk/2/hi/health/8462358.stm

(BBC Website English) 
http://news.bbc.co.uk/2/hi/health/7334067.stm

(Guardian Newspaper English) 
http://www.theguardian.com/society/2011/mar/18/behaviour-drugs-four-year-olds

(Guardian Newspaper English) 
http://www.theguardian.com/society/2008/apr/07/mentalhealth.drugs

Medication error:

(BBC website English) 
http://news.bbc.co.uk/2/hi/health/8465351.stm

Public seminar on immunization: 
http://www.youtube.com/channel/UCp33Uo6K2prznORDvB_2j8g

Regular Student Consultation Hours
Every Tuesday at 11:00am - 12:00pm
Office

2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong SAR, China